Pepticore

Company Overview

Snapshot

Founded in February 2024, Pepticore operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of novel antibacterial and antifungal drugs.

Business overview

Pepticore is a subsidiary of Tarom Innovative Technologies, specializing in the development of breakthrough antibacterial and antifungal drugs. Its core product, PheLiz, is an antibiotic designed to be effective against a broad spectrum of bacterial and fungal species, including antibiotic-resistant microbial strains, by exhibiting resilience to microbial resistance. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical industry with its B2B business model.

Company Intelligence Q&A

What is Pepticore's primary focus?

Pepticore is primarily focused on the development of innovative antibacterial and antifungal drugs to combat microbial resistance.

What is PheLiz?

PheLiz is Pepticore's lead product, an antibiotic active against a wide range of bacterial and fungal species, including those that are antibiotic-resistant, due to its unique structure and resilience to microbial resistance.

When was Pepticore founded?

Pepticore was founded in February 2024.

What is Pepticore's current product development stage?

Pepticore's product, PheLiz, is currently in the Clinical Trial stage, focusing on advancing its novel antibiotic for antibacterial and antifungal applications.

Which sector does Pepticore operate in?

Pepticore operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology.